Delisting risk
PASG · NASDAQ · Biotechnology

Passage Bio

Winding down neurodegenerative gene therapies while pursuing a merger with Remix Therapeutics.

$4.52
After-hours close−0.04 (−0.88%)
At close$4.56(+5.31%)
DateEstimateReportedSurprise
Nov 2026−$2.44
Aug 2026−$2.44−$2.440.0%
May 2026−$2.15−$2.36−9.8%
Mar 2026−$2.19−$4.08−86.3%
Nov 2025−$2.64−$2.44+7.6%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Feb 2020
Dec 2019
Jun 2019
Mar 2019
Dec 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 9, 2026−$2.44
Aug 10, 2026−$2.44−$2.440.0%
May 12, 2026−$2.15−$2.36−9.8%
Mar 3, 2026−$2.19−$4.08−86.3%
Nov 10, 2025−$2.64−$2.44+7.6%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 13, 2025
Mar 4, 2025
Nov 13, 2024
Aug 8, 2024
May 14, 2024
Mar 4, 2024
Nov 13, 2023
Aug 7, 2023
May 11, 2023
Mar 6, 2023
Nov 10, 2022
Aug 4, 2022
May 16, 2022
Mar 3, 2022
Nov 4, 2021
Aug 5, 2021
May 5, 2021
Mar 3, 2021
Nov 10, 2020
Aug 13, 2020
May 11, 2020
Feb 28, 2020
Dec 31, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018